Research brief

Orforglipron Study Results: ATTAIN and ACHIEVE Readouts

Real Peptides Research TeamEditorial

Updated September 30, 20269 min read

56 WORDS

Short answer

The most quoted figure in the orforglipron study results, roughly 12.4% mean weight reduction at 72 weeks, comes from a compound that isn't a peptide. Orforglipron is a chemically synthesised small molecule, and that one structural fact explains the once-daily oral dosing, the absence of a cold chain, and most of the manufacturing story around it.

Key takeaways

Orforglipron is a non-peptide small-molecule GLP-1 receptor agonist, structurally unrelated to semaglutide and tirzepatide, which is why it can be formulated as a once-daily tablet without an absorption enhancer.
ATTAIN-1 reported approximately 12.4% mean weight reduction at 72 weeks at 36 mg on the efficacy estimand, against roughly 0.9% for placebo.
ACHIEVE-1 reported A1C reductions of roughly 1.3% to 1.6% at 40 weeks from a baseline near 8.0%, with weight loss still trending downward at trial end.
The orforglipron study results differ between obesity and diabetes populations because incretin-driven weight response is consistently blunted in type 2 diabetes across the entire drug class.
A bioequivalence study is not a minor footnote: FDA guidance requires the 90% confidence intervals for AUC and Cmax to fall within 80% to 125% of the reference formulation.
Switch, maintenance and comorbidity-focused trials remain the least-reported and arguably most decisive part of the program.

Labs sourcing reference material ask us the same thing every week: what did these trials actually measure? Our team reads the readouts as they publish, and the recurring mistake is quoting one number from one press release as though it represents an entire Phase 3 program.

What do the orforglipron study results show?

The orforglipron study results from Eli Lilly's Phase 3 program report approximately 12.4% mean weight reduction at 72 weeks in ATTAIN-1 at the 36 mg dose, against roughly 0.9% on placebo, plus A1C reductions of about 1.3% to 1.6% at 40 weeks in ACHIEVE-1. Gastrointestinal events drove most discontinuations across both.

There is no single headline figure. The orforglipron study results span obesity trials, diabetes trials, a head-to-head against oral semaglutide, maintenance and switch designs, and formulation bioequivalence work, each with its own duration, population and statistical estimand. What follows covers what ATTAIN and ACHIEVE measured, why a non-peptide agonist behaves differently from injectable GLP-1 drugs, and which readouts are still pending.

What ATTAIN and ACHIEVE actually measured

Two trial families carry the program. ATTAIN is the obesity work, ACHIEVE is the type 2 diabetes work, and they are not interchangeable.

ATTAIN-1 enrolled adults with obesity, or overweight with a weight-related comorbidity, without diabetes, running 72 weeks across 3 mg, 12 mg and 36 mg once-daily arms versus placebo. The sponsor reported roughly 12.4% mean weight reduction at the top dose on the efficacy estimand against roughly 0.9% for placebo, with the treatment-regimen estimand landing lower. ATTAIN-2 ran a comparable design in adults who also had type 2 diabetes and reported roughly 10.5% versus about 2.2%.

That gap isn't a fluke. Weight response to incretin therapy is consistently blunted in people with type 2 diabetes across the whole drug class, which is why the orforglipron obesity study and the orforglipron diabetes study can't be read against each other as if they were the same experiment. Read the orforglipron study results population by population and the numbers stop contradicting each other.

ACHIEVE-1 tested the compound as monotherapy in type 2 diabetes inadequately controlled by diet and exercise over 40 weeks, reporting A1C reductions of roughly 1.3% to 1.6% from a baseline near 8.0%, with weight loss near 7.9% at the top dose that had not plateaued when the trial ended. It was published in the New England Journal of Medicine and presented at the American Diabetes Association Scientific Sessions in 2025.

Tolerability tracked the class. Nausea, vomiting, diarrhoea and constipation dominated adverse events, mostly mild to moderate, mostly during dose escalation, with discontinuations for adverse events reaching high single digits at the highest dose.

Why the pill works without a peptide bond

Orforglipron (development code LY3502970) is a non-peptide, small-molecule agonist of the GLP-1 receptor. Semaglutide and tirzepatide are peptides, which is why they are injected, or in oral semaglutide's case paired with the absorption enhancer SNAC (salcaprozate sodium) and taken fasting with a small volume of water. Orforglipron survives the gut on its own chemistry, which is why the orforglipron pill study protocols carried no food or water restrictions.

Preclinical characterisation describes it as a partial, G-protein biased agonist with limited beta-arrestin recruitment. Beta-arrestin is the scaffold protein that drags an activated receptor inside the cell and switches it off, so biased signalling in theory preserves receptor availability at the membrane. Research suggests this is part of why a partial agonist can produce full-agonist-like clinical effects, though none of the Phase 3 trials were designed to isolate that mechanism.

Here's the part most coverage gets wrong. People assume partial agonism should mean fewer gastrointestinal events. The reported rates don't support that. Nausea and vomiting show up at broadly class-typical frequencies, which points to GI tolerability being governed by receptor occupancy in the gut and titration speed, not by signalling bias.

The downstream consequence is manufacturing. A small molecule scales through conventional chemical synthesis rather than solid-phase peptide synthesis, and tablets don't need 2 to 8 degrees Celsius storage. For laboratories comparing oral and injectable GLP-1 receptor pharmacology at the bench, that changes handling too: our orforglipron research capsules ship with batch documentation rather than cold-chain packaging.

The trials nobody quotes: switch, maintenance, hypertension and bioequivalence

The orforglipron study results that will decide how this compound gets used in practice are mostly still unpublished, and they sit outside the two flagship trials.

An orforglipron switch study takes participants already stabilised on an injectable GLP-1 receptor agonist and transitions them onto the oral compound, measuring whether weight and glycaemic control hold through the changeover rather than measuring fresh weight loss. An orforglipron maintenance study asks the harder question: after weight has come off, what happens on continued dosing versus withdrawal. Across this class, discontinuation is consistently followed by substantial regain, so maintenance data arguably matter more to long-term outcomes than any 72-week headline.

Blood pressure appears two ways. Systolic blood pressure has featured as a secondary endpoint in the obesity trials, and anyone hunting a definitive orforglipron hypertension study readout should check ClinicalTrials.gov registrations directly, because sponsor topline releases have so far led with weight and A1C.

An orforglipron bioequivalence study is Phase 1 crossover work in healthy volunteers comparing the tablet used in Phase 3 against the intended commercial tablet. Under FDA guidance, the 90% confidence intervals for AUC (area under the curve) and Cmax must fall within 80% to 125% of the reference product. Unglamorous, and non-negotiable: without it, Phase 3 efficacy data can't be bridged to whatever eventually reaches a pharmacy shelf. ACHIEVE-3, the head-to-head against oral semaglutide, is the one comparison in the program that pits two oral agents directly against each other.

None of this is guidance for a person. These compounds are supplied for laboratory research only, never for human or animal consumption, and anyone weighing a real GLP-1 decision should talk to their physician, or where an animal is involved, talk to their veterinarian.

Orforglipron study results at a glance: a trial-by-trial index

The table below indexes the main studies by population, endpoint and reporting status, because the orforglipron study results are frequently misquoted by mixing trials with different designs. Status reflects public reporting at the time of writing.

Study	Population and design	Primary endpoint focus	Reporting status	Bottom line for researchers
ATTAIN-1	Adults with obesity, or overweight with comorbidity, without diabetes; 72 weeks; 3, 12 and 36 mg versus placebo	Percent change in body weight	Topline released by sponsor and published in the New England Journal of Medicine	The reference readout everyone cites, roughly 12.4% at 36 mg on the efficacy estimand
ATTAIN-2	Adults with obesity and type 2 diabetes; 72 weeks	Percent change in body weight, with A1C as secondary	Topline reported by the sponsor	Weight response is blunted in diabetes, roughly 10.5% versus about 2.2% placebo
ACHIEVE-1	Type 2 diabetes inadequately controlled on diet and exercise; 40 weeks; monotherapy	A1C change from baseline	Published in NEJM, presented at ADA Scientific Sessions 2025	A1C fell roughly 1.3% to 1.6%; weight had not plateaued at week 40
ACHIEVE-3	Head-to-head against oral semaglutide in type 2 diabetes	Comparative A1C reduction	Topline announced by sponsor, full presentation pending	The only direct oral versus oral comparison in the program
Switch and maintenance designs	Transition from injectable GLP-1 therapy, or continued dosing versus withdrawal after weight loss	Durability of weight and glycaemic control	Ongoing, registered on ClinicalTrials.gov	These answer the durability question a 72-week trial structurally cannot
Bioequivalence studies	Phase 1 crossover in healthy volunteers, clinical versus commercial tablet	AUC and Cmax comparability	Standard regulatory requirement, rarely published separately	Without them, efficacy data cannot be bridged to the marketed tablet

What If: Reading the Trial Data Scenarios

What if orforglipron's weight loss looks weaker than tirzepatide's?

Compare populations and estimands before drawing a conclusion. SURMOUNT-1 reported roughly 20.9% mean weight reduction at 72 weeks with tirzepatide 15 mg in adults without diabetes, so on absolute weight change the injectable dual GIP and GLP-1 receptor agonist sits ahead of the reported orforglipron study results. The oral compound's argument was never head-to-head superiority. It is manufacturing scale, room-temperature distribution and the removal of an injection step.

What if a trial is registered but has no published results?

Treat the registration as a design document, not as evidence. A ClinicalTrials.gov entry lists population, arms, endpoints and estimated completion date, which tells you exactly what will be measured and nothing at all about the outcome. Sponsor press releases typically arrive first, peer-reviewed publication follows months later, and the two often emphasise different estimands from the same dataset.

What if the press release figure doesn't match the journal paper?

Check whether you are comparing an efficacy estimand against a treatment-regimen estimand. The efficacy estimand models what happens if participants remain on treatment as assigned. The treatment-regimen estimand includes everyone regardless of whether they stopped early. Same trial, different question, and gaps of one to two percentage points between the two are entirely routine rather than evidence of anything being misreported.

What if reference material doesn't match the published characterisation?

Stop and read the certificate of analysis before running anything downstream. Identity should be confirmed against expected molecular weight by mass spectrometry, with purity quantified by HPLC, and any discrepancy in appearance, solubility behaviour or assigned lot number is worth raising with the supplier before the material enters an experiment. Silent substitution is far more common in this market than contamination is.

The unglamorous truth about oral GLP-1 hype

Let's be direct about this: the orforglipron study results are not an efficacy breakthrough. On absolute weight reduction the compound sits below injectable tirzepatide and broadly in the range of injectable semaglutide. What is genuinely new is form factor and supply. A daily tablet produced by conventional chemical synthesis can be manufactured at volumes peptide synthesis has never reached, and it ships without refrigeration. That is an access story, not a potency story, and conflating the two is exactly how expectations get set wrong.

Background on the compound class, current regulatory status and our published batch documentation sit on the orforglipron overview page, the certificates of analysis library and the broader research catalog.

The orforglipron study results will keep arriving in fragments for years, and the fragments that reshape practice will be the boring ones: whether weight holds after a switch from injectable therapy, whether maintenance dosing prevents regain, whether a commercial tablet behaves like the clinical one. Headline percentages travel fast because they are easy to repeat. Durability data travel slowly because they take four years to generate. If you are building a literature review, index by trial name and estimand rather than by press cycle, and the picture stops looking contradictory almost immediately.

References

Peer-reviewed sources on Orforglipron indexed in PubMed, listed for research context. Real Peptides supplies Orforglipron for laboratory research use only.

Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis. Endocrinology, diabetes & metabolism, 2025. PMID 41296780. doi:10.1002/edm2.70134
Orforglipron in type 2 diabetes mellitus and obesity: an overview. Expert review of clinical pharmacology, 2025. PMID 41275408. doi:10.1080/17512433.2025.2594493
Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis. Obesity science & practice, 2024. PMID 38414573. doi:10.1002/osp4.743
Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials. Archives of endocrinology and metabolism, 2024. PMID 39420937. doi:10.20945/2359-4292-2023-0469
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism: clinical and experimental, 2023. PMID 37852529. doi:10.1016/j.metabol.2023.155710
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet (London, England), 2026. PMID 41765029. doi:10.1016/S0140-6736(26)00202-3
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. Clinical pharmacology in drug development, 2026. PMID 40888509. doi:10.1002/cpdd.1594
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature medicine, 2026. PMID 42120723. doi:10.1038/s41591-026-04386-7

Questions

ATTAIN-1, the 72-week Phase 3 obesity trial, reported approximately 12.4% mean body weight reduction at the 36 mg once-daily dose on the efficacy estimand, compared with roughly 0.9% for placebo. ATTAIN-2, which enrolled adults with both obesity and type 2 diabetes, reported roughly 10.5% versus about 2.2% for placebo. The treatment-regimen estimand figures, which include participants who discontinued, are lower than the efficacy estimand figures in both trials.

Semaglutide and tirzepatide are peptide molecules, which is why they are given by subcutaneous injection or, for oral semaglutide, combined with the absorption enhancer SNAC and taken under fasting conditions. Orforglipron is a non-peptide small molecule that is orally bioavailable on its own chemistry, so trial protocols carried no food or water restrictions. It is also described in preclinical work as a partial, G-protein biased GLP-1 receptor agonist with limited beta-arrestin recruitment.

Orforglipron is an investigational compound and is not an approved drug product. Its Phase 3 program has reported topline and published data in obesity and type 2 diabetes, and regulatory submissions have been discussed publicly by the sponsor, but approval status should be verified against current FDA announcements rather than trial coverage. Research-grade material supplied for laboratory use is not a medicine and is not intended for human or animal consumption.

ATTAIN is the Phase 3 obesity arm of the orforglipron clinical study program. ATTAIN-1 enrolled adults with obesity, or overweight with at least one weight-related comorbidity, but without type 2 diabetes, and ran 72 weeks across 3 mg, 12 mg and 36 mg once-daily arms against placebo. ATTAIN-2 used a comparable design in adults who also had type 2 diabetes, which is why its weight reduction figures are lower.

Gastrointestinal adverse events dominated: nausea, vomiting, diarrhoea and constipation, mostly mild to moderate and concentrated during the dose-escalation phase. Discontinuation due to adverse events reached high single digits at the highest dose arms. This tolerability profile is broadly consistent with the wider GLP-1 receptor agonist class rather than distinct from it.

A bioequivalence study is Phase 1 crossover work in healthy volunteers that compares the pharmacokinetics of the tablet used in Phase 3 trials against the intended commercial tablet formulation. Under FDA guidance, the 90% confidence intervals for AUC (area under the curve) and Cmax must fall within 80% to 125% of the reference product. Without this bridging data, efficacy results from the clinical formulation cannot be applied to a different marketed tablet.

Weight response to incretin-based therapy is consistently blunted in people with type 2 diabetes across the entire drug class, not just with orforglipron. Contributing factors discussed in the literature include background glucose-lowering medications, reduced glycosuria as glycaemic control improves, and differences in baseline metabolic state. That is why the orforglipron obesity study and the orforglipron diabetes study should never be compared as if they measured the same population.

A switch study enrols participants already stabilised on an injectable GLP-1 receptor agonist and transitions them onto the oral compound, then measures whether weight loss and glycaemic control are maintained through and after the transition. It answers a different question from a treatment-naive trial: not how much weight comes off, but whether an oral agent can hold ground already gained. These designs are ongoing and registered on ClinicalTrials.gov.

Systolic blood pressure has appeared as a secondary endpoint within the obesity trial program, consistent with how weight-loss trials in this class typically report cardiometabolic secondary measures. Anyone looking for a dedicated orforglipron hypertension study readout should check ClinicalTrials.gov registrations directly, because sponsor topline releases have so far led with body weight and A1C rather than blood pressure endpoints.

There is no established consumer price, because the compound is investigational rather than commercially marketed. Research-grade material for laboratory use is priced by quantity, purity specification and batch documentation, and costs vary widely between suppliers. Anyone sourcing for research should weigh the certificate of analysis, HPLC purity figure and mass spectrometry identity confirmation ahead of headline price, since unverified material is the most expensive thing a lab can buy.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA